Early Stage Licensing Opportunities (ESLO)
At Kengal, we empower early-stage researchers, academic institutions, and life sciences companies to transform scientific innovation into clinical reality. Our mission is to accelerate the development of novel therapeutic molecules by providing comprehensive, end-to-end asset development management.
From initial asset identification to IND readiness and filing, we guide sponsors through every critical milestone.
Our services include:
• Asset Identification – Evaluating and selecting promising candidates with therapeutic potential
• In-depth Asset Profiling – Building detailed scientific and regulatory profiles to support development strategy
• Asset Validation – Conducting unbiased, data-driven studies to confirm viability and safety
• IND-Enabling Studies – Executing pharmacology, toxicology, and bridging validation studies to meet regulatory requirements
• IND Submission Support – Preparing and filing complete IND applications with precision and regulatory insight
By combining scientific rigor with strategic foresight, Kengal helps sponsors de-risk early development and position their assets for successful clinical entry. Whether you're advancing a first-in-class molecule or repurposing an existing compound, we serve as your trusted partner in navigating the complex journey from bench to bedside.